KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Recommendation of “Buy” by Analysts

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has been assigned an average recommendation of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $23.80.

KALV has been the topic of several research analyst reports. Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Finally, TD Cowen assumed coverage on KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $30.00 target price for the company.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 6,669 shares of KalVista Pharmaceuticals stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $11.97, for a total value of $79,827.93. Following the transaction, the chief executive officer now owns 287,811 shares of the company’s stock, valued at approximately $3,445,097.67. This trade represents a 2.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Paul K. Audhya sold 3,125 shares of KalVista Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $30,687.50. Following the completion of the transaction, the insider now directly owns 100,334 shares in the company, valued at $985,279.88. This represents a 3.02 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders bought 236,055 shares of company stock valued at $2,162,146 and sold 17,292 shares valued at $184,625. 10.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently bought and sold shares of KALV. Frazier Life Sciences Management L.P. grew its stake in KalVista Pharmaceuticals by 32.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company’s stock valued at $41,400,000 after acquiring an additional 1,200,000 shares in the last quarter. Woodline Partners LP grew its stake in KalVista Pharmaceuticals by 111.8% during the 4th quarter. Woodline Partners LP now owns 1,288,401 shares of the specialty pharmaceutical company’s stock valued at $10,913,000 after acquiring an additional 680,148 shares in the last quarter. Vestal Point Capital LP grew its stake in KalVista Pharmaceuticals by 19.3% during the 4th quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company’s stock valued at $40,402,000 after acquiring an additional 770,000 shares in the last quarter. Tang Capital Management LLC grew its stake in KalVista Pharmaceuticals by 13.2% during the 4th quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company’s stock valued at $41,451,000 after acquiring an additional 572,300 shares in the last quarter. Finally, Stempoint Capital LP purchased a new position in KalVista Pharmaceuticals during the 4th quarter valued at about $8,409,000.

KalVista Pharmaceuticals Stock Down 0.9 %

NASDAQ:KALV opened at $11.89 on Friday. The company has a market cap of $591.12 million, a PE ratio of -3.27 and a beta of 0.76. The business’s 50 day moving average is $10.13 and its two-hundred day moving average is $10.27. KalVista Pharmaceuticals has a 52 week low of $7.30 and a 52 week high of $15.50.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).